Wszystkie zdjęcia(1)
Kluczowe dokumenty
SHP001
MISSION® Lentiviral Packaging Mix
MISSION® Lentiviral Packaging Mix
Production of replication incompetent viral particles
Synonim(y):
Lentiviral Packaging, Lentiviral Packaging Kit
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wybierz wielkość
0.25 ML
2280,00 zł
1.7 ML
7880,00 zł
2280,00 zł
Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
Poproś o zamówienie zbiorczeWięcej informacji
Wybierz wielkość
Zmień widok
0.25 ML
2280,00 zł
1.7 ML
7880,00 zł
About This Item
Kod UNSPSC:
41106609
NACRES:
NA.51
2280,00 zł
Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
Poproś o zamówienie zbiorczeWięcej informacji
Polecane produkty
Powiązane kategorie
Opis ogólny
The MISSION® shRNA product line is centered on a transfer vector-based RNAi library against annotated mouse and human genes that can be used in conjunction with this Lentiviral Packaging Mix. In this packaging system, the pseudo-typing with VSV-G broadens the viral tropism associated with the virus.[1] Therefore, these lentiviral particles can efficiently deliver the transfer sequence of interest to a wide variety of cell types, including primary and non-dividing cells.[2][3]
The MISSION® Lentiviral Packaging Mix is an optimized formulation of two plasmids expressing the key HIV packaging genes and a heterologous viral envelope gene.
Lentiviral particles are generated from three main components:
The Lentiviral Packaging Mix contains the first two components; it is designed to be co-transfected along with a compatible lentiviral transfer vector in order to create high-titer pseudo-typed lentiviral particles used for downstream transduction applications.[4]
The MISSION® Lentiviral Packaging Mix is an optimized formulation of two plasmids expressing the key HIV packaging genes and a heterologous viral envelope gene.
Lentiviral particles are generated from three main components:
- The packaging vector, which contains the minimal set of lentiviral genes required to generate the virion structural proteins and packaging functions.
- The vesicular stomatitis virus G-protein envelope vector, which provides the heterologous envelope for pseudotyping.
- The shRNA transfer vector, which contains the sequence of interest as well as the cis acting sequences necessary for RNA production and packaging.
The Lentiviral Packaging Mix contains the first two components; it is designed to be co-transfected along with a compatible lentiviral transfer vector in order to create high-titer pseudo-typed lentiviral particles used for downstream transduction applications.[4]
Zastosowanie
Inne uwagi
Lentiviral particles are produced using a third-generation packaging system, which has many features that lead to enhanced biosafety.[7][3] Recombinant lentiviruses produced with the MISSION Lentiviral Packaging Mix have not been shown to produce replication competent viral particles because of designed safety features. Users should consult and observe their own institutional guidelines before working with such viral systems.[8]
Informacje prawne
Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense .
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Ta strona może zawierać tekst przetłumaczony maszynowo.
Kod klasy składowania
10 - Combustible liquids
Klasa zagrożenia wodnego (WGK)
WGK 2
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Wybierz jedną z najnowszych wersji:
Certyfikaty analizy (CoA)
Lot/Batch Number
Przepraszamy, ale COA dla tego produktu nie jest aktualnie dostępny online.
Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Klienci oglądali również te produkty
NIH Guidelines for Research Involving Recombinant DNA Molecules
N.I.H. Memorandum (2002)
T Dull et al.
Journal of virology, 72(11), 8463-8471 (1998-10-10)
Vectors derived from human immunodeficiency virus (HIV) are highly efficient vehicles for in vivo gene delivery. However, their biosafety is of major concern. Here we exploit the complexity of the HIV genome to provide lentivirus vectors with novel biosafety features.
Toufik Abbas-Terki et al.
Human gene therapy, 13(18), 2197-2201 (2003-01-25)
RNA interference (RNAi) is a form of posttranscriptional gene silencing mediated by short double-stranded RNA, known as small interfering RNA (siRNA). These siRNAs are capable of binding to a specific mRNA sequence and causing its degradation. The recent demonstration of
Wenwen Chien et al.
Journal of Cancer, 9(24), 4762-4773 (2018-12-28)
This study is an unbiased genomic screen to obtain functional targets for increased effectiveness of dasatinib in pancreatic cancer. Dasatinib, a multi-targeted tyrosine kinase inhibitor, is used in clinical trials for treatment of pancreatic cancer; however, intrinsic and acquired resistance
Heterogenous ribonucleoprotein A18 (hnRNP A18) promotes tumor growth by increasing protein translation of selected transcripts in cancer cells.
Chang ET
Oncotarget, 7(9), 10578-10593 (2016)
Produkty
MISSION shRNA reduce the expression of specific target genes by targeting the specific mRNA therefore reducing the corresponding protein expression.
When shRNA is delivered using lentiviral vectors, the sequence encoding the shRNA is integrated into the genome and the knockdown effect is passed on to daughter cells, continuing gene silencing.
Protokoły
Preparation of the Lentiviral Transduction Particles Using Packaging Plasmid Mix
Active Filters
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej
